A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma

Not Recruiting

Trial ID: NCT01572519


The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.

Official Title

An Open-label, Multicenter, Phase 1/2 Study of JNJ-40346527, an FMS Inhibitor, in Subjects With Relapsed or Refractory Hodgkin Lymphoma

Stanford Investigator(s)

Lauren Maeda
Lauren Maeda

Clinical Associate Professor, Medicine - Oncology


Inclusion Criteria:

- Patients with histopathologically confirmed initial diagnosis of Hodgkin lymphoma and who
have disease that has relapsed or is refractory that is progressing or active and requires
treatment after at least 1 appropriate therapy

Exclusion Criteria:

   - Known brain metastases or leptomeningeal disease

   - Other malignancy within past 5 years

   - Has any condition that, in the opinion of the investigator, would make study
   participation not be in the best interest (eg, compromise the well-being) of the
   patient or that could prevent, limit, or confound the protocol-specified assessments

   - QTc prolongation at screening or other factors that increase the risk of QT
   prolongation such as diagnosis or family history of long-QT syndrome, diagnosed or
   suspected congenital long QT syndrome, or concomitant use of medication that can
   prolong the QT interval

   - Taking CYP3A4 substrate drugs with a narrow therapeutic index (eg, alfentanil,
   astemizole, sirolimus, tacrolimus, terfenadine)


drug: Phase 1, Cohort 1

drug: Phase 1, Cohort 2

drug: Phase 1, Cohort 3

drug: Phase 1, Cohort 4

drug: Phase 2

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sarah Daadi

New Trial Alerts

Receive email alerts when trials open to patients.